- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03862768
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
1. mars 2019 oppdatert av: Shanghai Zhongshan Hospital
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment: A Prospective, Multicenter, Randomized Trial
This study evaluates the efficacy and safety of surgical intervention in patients with focally progressive GISTs after imatinib treatment.
The enrolled patients will be randomized to receive surgery following imatinib 400 milligram per day (MG/d) or only tyrosine kinase inhibitor (Imatinib 600 MG/d or Sunitinib 37.5 MG/d).
Studieoversikt
Status
Ukjent
Intervensjon / Behandling
Detaljert beskrivelse
Imatinib is the first-line treatment for advanced GIST with a satisfactory response rate, but complete remission rarely happens.
Besides, drug resistance can occur during the treatment and the median time of drug resistance is about 20-24 months.
Once drug resistance occurs, the patient's condition will progress rapidly.
As a salvage treatment, the effect of increasing the dose of imatinib or switching to sunitinib is very limited.
Progress after imatinib treatment usually involves two conditions, focal progression and extensive progression.
For local progression, all resistant lesions can be completely resected; extensive progression refers to resistance progression in multiple sites, and progressive lesions cannot be completely removed.
The present study is aimed to assess the benefits of surgical resection of imatinib-resistant lesions in patients with localized disease.
Studietype
Intervensjonell
Registrering (Forventet)
92
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 75 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients whose pathology is clearly diagnosed as recurrent/metastatic GIST, have undergone standardized imatinib treatment, and the disease progresses during the treatment;
- The lesions with progress are confined to one organ, and the number is ≤3; after evaluation by relevant professional surgeons or multidisciplinary team discussion, it is considered that the progressive lesions can be completely and safely removed without affecting the organ function;
- Age: 18 years old ≤ age ≤ 75 years old;
- No other malignant tumors occurred within five years;
- Eastern Cooperative Oncology Group (ECOG) physical status score <2 points;
- American Society of Anesthesiologists (ASA) score <3 points;
- There are no restrictions on gender and race;
- Patients with informed consent.
Exclusion Criteria:
- The patient has other serious comorbidities and cannot tolerate surgery: such as severe cardiopulmonary disease, cardiac function in grade 2 or lower, pulmonary infection, moderate to severe chronic obstructive pulmonary disease (COPD), etc., combined with severe diabetes and/or kidney Insufficient function, combined with severe hepatitis and/or functional Child-pugh grade C or a grade B that is clearly difficult to correct, combined with severe malnutrition;
- Patients with extensive disease progress;
- Imatinib primary resistant patients;
- Patients with other diseases requiring simultaneous surgical intervention, such as gallstones; inguinal hernia;
- Disease-related complications such as bleeding, perforation, and obstruction;
- Pregnant or lactating women;
- The patient has a serious mental illness;
- Patients with other malignant tumors within five years;
- The patient has participated in or is participating in other clinical studies or is using other tyrosinekinase inhibitors.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Surgery following imatinib
Surgery requires at least removal of all drug-resistant lesions.
Imatinib 400 MG/d should be taken once the patients resume oral diet.
|
Surgery requires at least removal of all drug-resistant lesions.
Imatinib 400 MG/d should be taken once the patients resume oral diet
|
|
Aktiv komparator: Imatinib escalation or sunitinib
Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs.
There is no high-level evidence to suggest which method is better.
So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
|
Imatinib 600 MG/d
Sunitinib 37.5 MG/d
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival
Tidsramme: one year
|
Progression-free survival will be defined as time from the start of treatment until progression (documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions) or death, whichever comes first.
|
one year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: one year
|
Overall survival will be defined as time from the start of treatment until death from any cause
|
one year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. juli 2019
Primær fullføring (Forventet)
1. juni 2021
Studiet fullført (Forventet)
1. desember 2021
Datoer for studieregistrering
Først innsendt
27. februar 2019
Først innsendt som oppfylte QC-kriteriene
1. mars 2019
Først lagt ut (Faktiske)
5. mars 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
5. mars 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. mars 2019
Sist bekreftet
1. februar 2019
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer, bindevev og mykt vev
- Neoplasmer etter histologisk type
- Neoplasmer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Neoplasmer, bindevev
- Gastrointestinale stromale svulster
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Proteinkinasehemmere
- Sunitinib
- Imatinibmesylat
Andre studie-ID-numre
- B2018-297
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .